Multimarker Gene Analysis of Circulating Tumor Cells in Pancreatic Cancer Patients: A Feasibility Study

Publikation: Beitrag in FachzeitschriftForschungsartikelBeigetragenBegutachtung


  • Andreia de Albuquerque - , Klinikum Chemnitz gGmbH, Technische Universität Dresden (Autor:in)
  • Ilja Kubisch - , Klinikum Chemnitz gGmbH (Autor:in)
  • Georg Breier - , Institut für Pathologie (Autor:in)
  • Gudrun Stamminger - , Klinikum Chemnitz gGmbH (Autor:in)
  • Nikos Fersis - , Klinikum Chemnitz gGmbH (Autor:in)
  • Astrid Eichler - , Universitätsklinikum Frankfurt (Autor:in)
  • Sepp Kaul - , Klinikum Chemnitz gGmbH (Autor:in)
  • Ulrich Stoelzel - , Klinikum Chemnitz gGmbH (Autor:in)


Objective:The aim of this study was to develop an immunomagnetic/real-time reverse transcriptase polymerase chain reaction (RT-PCR) assay and assess its clinical value for the molecular detection of circulating tumor cells (CTCs) in peripheral blood of pancreatic cancer patients. Methods: The presence of CTCs was evaluated in 34 pancreatic cancer patients before systemic therapy and in 40 healthy controls, through immunomagnetic enrichment, using the antibodies BM7 and VU1D9 [targeting mucin 1 and epithelial cell adhesion molecule (EpCAM), respectively], followed by real-time RT-PCR analysis of the genes KRT19, MUC1, EPCAM, CEACAM5 and BIRC5. Results: The developed assay showed high specificity, as none of the healthy controls were found to be positive for the multimarker gene panel. CTCs were detected in 47.1% of the pancreatic cancer patients before the beginning of systemic treatment. Shorter median progression-free survival (PFS) was observed for patients who had at least one detectable tumor-associated transcript, compared with patients who were CTC negative. Median PFS time was 66.0 days [95% confidence interval (Cl) 44.8-87.2] for patients with baseline CTC positivity and 138.0 days (95% Cl 124.1-151.9) for CTC-negative patients (p = 0.01, log-rank test). Conclusion: Our results suggest that in addition to the current prognostic methods, CTC analysis represents a potential complementary tool for prediction of outcome in pancreatic cancer patients. Copyright (C) 2012 S. Karger AG, Basel


Seiten (von - bis)3-10
PublikationsstatusVeröffentlicht - 2012

Externe IDs

Scopus 84856034107
WOS 000300757500002
PubMed 22270149
ORCID /0000-0002-9467-780X/work/147674926


Ziele für nachhaltige Entwicklung


  • Circulating tumor cells, Pancreatic cancer, Reverse transcriptase real-time polymerase chain reaction